Vermillion Performs an Estimated 6,155 OVA1 Tests in 2010 | GenomeWeb

Vermillion this week announced it had performed an estimated 2,935 OVA1 ovarian cancer tests during the fourth quarter ended Dec. 31, 2010 and an estimated 6,155 tests in all of 2010.

The fourth-quarter sales number represented a 48.8 percent increase over the third quarter of 2010, the company said in a statement, and the full-year 2010 figure of 6,155 exceeded the company's adjusted 2010 guidance of 5,000 to 5,500 tests, although it fell short of its initial 8,000 to 10,000 test guidance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.